# Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

> **NCT01890434** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 478 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Gadobutrol (Gadavist, Gadovist, BAY86-4875)

## Key facts

- **NCT ID:** NCT01890434
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-26
- **Primary completion:** 2016-08-06
- **Final completion:** 2016-11-10
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890434, "Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01890434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*